CoChat
Sign Up
Cited by 124Endometrial and Cervical Cancer TreatmentsOvarian cancer diagnosis and treatmentGynecological conditions and treatments

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Management of women with clear cell endometrial cancer

Olawaiye, Alexander B., Boruta, David M.·2009·Gynecologic Oncology
DOI 10.1016/j.ygyno.2009.02.003
Open this paper in CoChat — free account

Abstract

Objective Clear cell endometrial cancer (CCE) is an uncommon but important disease because of its aggressive behavior. Furthermore, prospective, randomized studies are either too difficult or impossible because of the small number of women affected. This review explores the differences between clear cell and endometrioid endometrial cancer. In addition, it uses available evidence to determine the best approach to management.Methods Medline was searched between January 1, 1966 and December 31, 2008 for all publications in English where the studied population included women diagnosed with CCE. Qualifying studies must have had at least 30 patients.Results Clear cell histology is diagnosed in less than 6% of all endometrial cancers and its incidence increases with age. Diagnosis can be made using the same tests that are used in the diagnosis of other types of endometrial cancer. Clear cell histology is morphologically and genetically different from the more prevalent endometrioid endometrial cancer histology. It shares many similarities with clear cell neoplasms of the ovary and kidney. Comprehensive surgical staging is critical in order to plan appropriate postoperative management. Adjuvant pelvic and/or whole abdominal radiotherapy have not been shown to be clearly beneficial in women diagnosed with clear cell endometrial cancer. Adjuvant chemotherapy with cisplatinum, taxol and doxorubicin either in a doublet or triplet combination has demonstrated efficacy.Conclusions Women diagnosed with CCE require comprehensive surgical staging. Platinum based adjuvant chemotherapy in a doublet or triplet format in combination with paclitaxel and/or doxorubicin should be considered as part of treatment of these women. Careful long term surveillance following treatment is indicated given the higher rate of recurrence compared to endometrioid endometrial cancer.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2009.02.003

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The combination of carboplatin (AUC 5-6) and paclitaxel (175mg/m2) used for six cycles demonstrates efficacy in treatment, and this combination is better tolerated and less toxic compared to the use of doxorubicin, carboplatin, and paclitaxel triple therapy.

    “The combination of carboplatin (AUC 5-6) and paclitaxel (175mg/m2) used for six cycles demonstrates efficacy in treatment, and this combination is better tolerated and less toxic compared to the use of doxorubicin, carboplatin, and paclitaxel triple therapy [8, 25, 26].”

    From Clear cell carcinoma arising from abdominal wall endometriosis—A report on two cases and literature review (2022) · cites this paper as [25]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Averette, 1987, Surgical staging of gynecologic malignancies, Cancer, 60, 2010, 10.1002/1097-0142(19901015)60:8+<2010::AID-CNCR2820601512>3.0.CO;2-Y · DOI

Cited by

Sorted by citations

Related

Metadata

Authors
Olawaiye, A. B., & Boruta, D. M.
Affiliations
  • UPMC Health System (US)
  • Harvard University (US)
Corresponding author
  • Olawaiye, Alexander B.
  • Boruta, David M.
ORCID
Venue
Gynecologic Oncology
Publisher
Elsevier BV
Published
2009-05
Volume
113
Issue
2
Pages
277-283
ISSN
0090-8258 (ISSN-L)
DOI
10.1016/j.ygyno.2009.02.003
OpenAlex
W76374557
Cited by
124
References
59
Citations by year
2026: 4 · 2025: 7 · 2024: 3 · 2023: 11 · 2022: 7 · 2021: 6 · 2020: 5 · 2019: 13 · 2018: 9 · 2017: 14 · 2016: 8 · 2015: 9 · 2014: 8 · 2013: 9 · 2012: 5
FWCI
0.60
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Gynecologic Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
Keywords
endometrioid endometrial cancer, surgical staging, adjuvant chemotherapy, cisplatin, paclitaxel, doxorubicin, adjuvant radiotherapy, recurrence, long-term surveillance, histological differences
MeSH terms
Female, Humans, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review